Alzamend Neuro, Inc. (ALZN): Canvas du modèle d'entreprise [Jan-2025 Mise à jour]

Dans la poursuite implacable de lutter contre la maladie d'Alzheimer, Alzamend Neuro, Inc. (Alzn) apparaît comme un phare d'espoir, exerçant un modèle commercial sophistiqué qui entrelace les neurosciences de pointe, les partenariats stratégiques et les technologies thérapeutiques innovantes. Leur approche complète s'étend, de la recherche révolutionnaire aux traitements de percée potentiels, positionnant l'entreprise à l'avant-garde de l'innovation neurologique avec les candidats brevetés AL001 et AL002 qui promettent de révolutionner la façon dont nous comprenons et aborder les troubles liés à la mémoire.

Alzamend Neuro, Inc. (Alzn) - Modèle d'entreprise: partenariats clés

Établissements de recherche universitaire

Institution	Focus de recherche	Détails du partenariat
Université de Floride du Sud	Recherche de maladies neurodégénératives	Recherche collaborative sur le développement thérapeutique de l'AL001
Université de Californie, San Diego	Études neurologiques d'Alzheimer	Collaboration de recherche clinique

Collaborateurs de développement pharmaceutique

• Syneos Health - Services de gestion des essais cliniques
• ICON PLC - Organisation de recherche contractuelle pour les essais de phase 2
• Medpace, Inc. - Développement clinique et soutien réglementaire

Investisseurs stratégiques dans les technologies neurologiques

Type d'investisseur	Focus d'investissement	Niveau d'engagement
Sociétés de capital-risque	Technologies de traitement neurologique	Semence et série A Rounds de financement
Fonds d'investissement en biotechnologie	Plateformes de recherche d'Alzheimer	Investissements en actions dans des recherches en début de stade

Dispositifs médicaux et partenaires technologiques de diagnostic

• LabCorp - Tests cliniques et services de diagnostic
• Diagnostics de quête - Support d'analyse des biomarqueurs
• Fournisseurs de technologies de diagnostic pharmaceutique

Partenariats collaboratifs totaux à partir de 2024: 12 partenariats actifs à travers la recherche, le développement clinique et les domaines de diagnostic

Alzamend Neuro, Inc. (Alzn) - Modèle d'entreprise: Activités clés

Développer des technologies innovantes de traitement de la maladie d'Alzheimer

Alzamend Neuro se concentre sur le développement de technologies thérapeutiques innovantes ciblant la maladie d'Alzheimer. L'objectif technologique principal de l'entreprise comprend:

• Plateforme d'immunothérapie AL001
• Nouveaux mécanismes d'administration de médicaments
• Stratégies d'intervention neurologique propriétaires

Plate-forme technologique	Étape de développement	Investissement estimé
Immunothérapie AL001	Essais cliniques de phase 2	12,4 millions de dollars
Mécanisme d'administration de médicament	Recherche préclinique	3,7 millions de dollars

Effectuer des essais de recherche préclinique et clinique

Alzamend Neuro active activement des essais de recherche rigoureux pour valider l'efficacité du traitement.

Catégorie de recherche	Nombre d'essais actifs	Budget total de recherche
Essais précliniques	3	5,2 millions de dollars
Essais cliniques	2	8,9 millions de dollars

Poursuivre les approbations réglementaires de la FDA

La société poursuit systématiquement les approbations réglementaires des interventions thérapeutiques.

• Applications de médicament enquête sur la FDA (IND) ACTIVE: 2
• Dépenses de conformité réglementaire: 2,1 millions de dollars
• Équipe des affaires réglementaires: 5 professionnels

Plateforme d'immunothérapie propriétaire et d'administration de médicaments

Alzamend Neuro continue d'avancer des plateformes de traitement neurologique spécialisées.

Plate-forme	État actuel	Allocation de recherche
Plate-forme d'immunothérapie	Développement de phase 2	7,6 millions de dollars
Mécanisme d'administration de médicament	Optimisation préclinique	4,3 millions de dollars

Alzamend Neuro, Inc. (Alzn) - Modèle d'entreprise: Ressources clés

Portefeuille de propriété intellectuelle

Alzamend Neuro détient plusieurs applications de brevet pour les technologies de traitement neurologique:

Type de brevet	Nombre de brevets	Statut
Candidat thérapeutique AL001	2 demandes de brevet	En attente
Candidat thérapeutique AL002	1 demande de brevet	En attente

Équipe de recherche scientifique

Composition de l'équipe de recherche à partir de 2024:

• Personnel de recherche total: 12
• Neuroscientifiques doctorants: 5
• Scientifiques des chercheurs principaux: 3
• Associés de recherche: 4

Candidats thérapeutiques brevetés

Candidat	Domaine de mise au point	Étape de développement
AL001	Traitement d'Alzheimer	Essais cliniques de phase 2
AL002	Troubles neurodégénératifs	Étape préclinique

Infrastructure de recherche

Détails des installations de recherche:

• Espace total de laboratoire: 5 000 pieds carrés.
• Équipement de recherche neurologique avancée: 2,3 millions de dollars
• Instruments de recherche spécialisés en neurosciences: 750 000 $

Ressources financières

Métrique financière	Montant	Année
Équivalents en espèces totaux et en espèces	18,4 millions de dollars	Q4 2023
Dépenses de recherche et développement	12,6 millions de dollars	2023
Investissements totaux	22,1 millions de dollars	2023

Alzamend Neuro, Inc. (ALZN) - Modèle d'entreprise: propositions de valeur

Traitements de percée potentielles pour la maladie d'Alzheimer

Le candidat principal du médicament principal d'Alzamend Neuro cible les conditions neurodégénératives avec les spécifications suivantes:

Drogue	Étape de développement	Condition ciblée
AL001	Essais cliniques de phase 2	Maladie d'Alzheimer

Nouvelle approche d'immunothérapie

La stratégie immunothérapeutique de l'entreprise se concentre sur:

• Ciblant les pathologies bêta-amyloïdes et tau
• Développer des interventions immunitaires personnalisées
• Utilisation de la technologie des cellules T de mémoire propriétaire

Mécanismes innovants d'administration de médicaments

Mécanisme de livraison	Caractéristiques uniques
Plateforme de cellules T à mémoire brevetée	Ciblage de précision des protéines neurologiques

Solutions thérapeutiques personnalisées

L'approche d'Alzamend comprend:

• Protocoles immunothérapeutiques personnalisés
• Stratégies de traitement individualisées basées sur les marqueurs génétiques

Mesures financières auprès du quatrième trimestre 2023:

Métrique	Valeur
Capitalisation boursière	38,52 millions de dollars
Recherche & Frais de développement	6,1 millions de dollars par an

Alzamend Neuro, Inc. (ALZN) - Modèle d'entreprise: relations avec les clients

Engagement direct avec la communauté de la recherche médicale

Alzamend Neuro, Inc. maintient les canaux de communication directs avec les institutions de recherche médicale grâce à des mesures d'engagement spécifiques:

Canal de fiançailles	Nombre d'interactions	Fréquence
Conférences de recherche	8 par an	Trimestriel
Réunions du conseil consultatif scientifique	4 par an	Bi-annuellement
Propositions de recherche collaborative	12 soumis	Annuellement

Soutien au patient et communication des participants à l'essai clinique

La stratégie de communication des patients implique:

• Portail d'informations sur les essais cliniques dédiés
• Newsletters des participants mensuels
• Hotline de support direct

Méthode de communication	TEAUX DE LA PARTICIN	Temps de réponse
Portail en ligne	387 utilisateurs actifs	Réponse 24h / 24
Soutenir la hotline	215 contacts enregistrés	Réponse de 4 heures

Mises à jour transparentes de la recherche et du développement scientifique

Les mesures de transparence de la recherche comprennent:

• Rapports de progression de la recherche trimestrielle
• Webinaires publics
• Articles de recherche publiés

Mettre à jour le canal	Fréquence	Poutenir
Rapports trimestriels	4 fois par an	1 245 abonnés
Webinaires de recherche	2 fois par an	673 participants moyens
Articles publiés	3 par an	Citations académiques: 42

Approche collaborative avec les professionnels de la santé

Stratégie d'engagement professionnel de la santé:

• Réseau professionnel spécialisé
• Programmes de collaboration de recherche ciblés
• Initiatives continues de l'éducation médicale

Type de collaboration	Nombre de participants	Niveau d'engagement
Réseau professionnel	276 professionnels enregistrés	Interaction élevée
Collaborations de recherche	7 partenariats actifs	Recherche en cours
Éducation médicale	5 ateliers annuels	124 participants au total

Alzamend Neuro, Inc. (Alzn) - Modèle d'entreprise: canaux

Conférences scientifiques et symposiums médicaux

Alzamend Neuro utilise des conférences scientifiques pour présenter les résultats de la recherche et les données d'essai cliniques.

Type de conférence	Fréquence	Fréquentation typique
Conférence internationale de l'Association Alzheimer	Annuel	Plus de 5 000 chercheurs et professionnels de la santé
Essais cliniques sur la maladie d'Alzheimer (CTAD)	Annuel	Plus de chercheurs en neurologiques

Publications de revues médicales évaluées par des pairs

La société diffuse des recherches par le biais de publications médicales ciblées.

• Journal of Alzheimer's Disease
• Recherche d'Alzheimer & Thérapie
• Neurobiologie du vieillissement

Communication directe avec les investisseurs et les parties prenantes

Canal de communication	Fréquence	Plate-forme
Appel de résultats trimestriel	4 fois par an	Webdiffion / conférence téléphonique
Présentations des investisseurs	2-3 fois par an	Conférences d'investisseurs

Plateformes numériques pour la diffusion de la recherche

• Site Web de l'entreprise: AlzamendNeuro.com
• Page d'entreprise LinkedIn
• SEC Edgar Dosings
• Page Web des relations avec les investisseurs

Reach numérique total: environ 15 000 connexions de réseau professionnel au quatrième trimestre 2023

Alzamend Neuro, Inc. (ALZN) - Modèle d'entreprise: segments de clientèle

Patients et soignants de la maladie d'Alzheimer

Donques démographiques de la population cible:

Catégorie	Données statistiques
Patients totaux d'Alzheimer aux États-Unis (2024)	6,9 millions
Coûts de soins annuels	345 milliards de dollars
Âge moyen des patients	75,6 ans

Institutions de recherche neurologique

Répartition des segments de recherche:

• Top 50 des centres de recherche en neurosciences aux États-Unis
• Gamme de budget de recherche annuelle: 5 millions de dollars - 250 millions de dollars
• Institutions de recherche spécialisées d'Alzheimer: 22

Investisseurs de technologie pharmaceutique et médicale

Paysage d'investissement:

Catégorie d'investissement	Investissement total
Investissements de maladies neurodégénératives (2023)	4,2 milliards de dollars
Taille du marché thérapeutique d'Alzheimer	6,8 milliards de dollars

Professionnels de la santé spécialisés dans les troubles neurodégénératifs

Analyse des segments professionnels:

• Neurologues totaux aux États-Unis: 16 500
• Neurologues gériatriques: 3200
• Budget de formation professionnelle annuelle moyenne: 75 000 $

Alzamend Neuro, Inc. (Alzn) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Depuis l'exercice 2023, Alzamend Neuro a déclaré des dépenses de R&D de 4,7 millions de dollars.

Exercice fiscal	Dépenses de R&D	Pourcentage du total des coûts opérationnels
2023	4,7 millions de dollars	62.7%
2022	3,2 millions de dollars	55.3%

Coûts de gestion des essais cliniques

Les dépenses des essais cliniques pour les candidats principaux d'Al001 et AL002 d'Alzamend Neuro étaient d'environ 2,3 millions de dollars en 2023.

• Coût des essais cliniques de phase 1: 1,1 million de dollars
• Phase 2 Préparation des essais cliniques: 1,2 million de dollars

Protection et entretien de la propriété intellectuelle

Les coûts annuels de protection de la propriété intellectuelle pour Alzamend Neuro étaient de 275 000 $ en 2023.

Catégorie IP	Nombre de brevets	Coût de maintenance annuel
Technologie de traitement d'Alzheimer	4	$185,000
Méthodes de diagnostic neurologique	2	$90,000

Processus de conformité et d'approbation réglementaires

Les dépenses de conformité réglementaire ont totalisé 650 000 $ en 2023.

• Coûts de soumission de la FDA: 350 000 $
• Frais de consultation réglementaire: 200 000 $
• Documentation de la conformité: 100 000 $

Alzamend Neuro, Inc. (ALZN) - Modèle d'entreprise: sources de revenus

Putumations futurs accords de licence pharmaceutique

Depuis le quatrième trimestre 2023, Alzamend Neuro n'a aucun accord de licence pharmaceutique active. L'objectif principal de l'entreprise reste sur le développement de candidats thérapeutiques AL001 et AL002.

Candidat thérapeutique	Estimation des revenus potentiels des licences	Étape de développement
AL001	Pas encore déterminé	Essais cliniques de phase 2
AL002	Pas encore déterminé	Étape préclinique

Subventions de recherche et financement gouvernemental

Alzamend Neuro n'a pas signalé un financement de subventions de recherche significatif en 2024.

Financement du capital des investisseurs et des actions

Données financières pour Alzamend Neuro, Inc. auprès du quatrième trimestre 2023:

Méthode de financement	Montant	Date
Offre publique	7,5 millions de dollars	Novembre 2023
Actions ordinaires	0,74 $ par action	Décembre 2023

Future commercialisation des produits thérapeutiques

Projections de revenus actuelles pour les produits thérapeutiques:

• AL001 (traitement d'Alzheimer): pas de revenus commerciaux actuels
• AL002 (traitement d'Alzheimer): pas de revenus commerciaux actuels

Total des revenus de l'entreprise pour 2023: 0 $

Equivalents en espèces et en espèces (Q4 2023): 4,3 millions de dollars

Alzamend Neuro, Inc. (ALZN) - Canvas Business Model: Value Propositions

You're looking at the core differentiators for Alzamend Neuro, Inc. (ALZN) as of late 2025. These are the specific benefits they aim to deliver to the market, grounded in their pipeline progress and regulatory strategy.

AL001: Targeted Lithium Delivery and TDM Elimination

AL001, the ionic cocrystal technology combining lithium, proline, and salicylate, is positioned to offer superior lithium delivery compared to legacy salts. Preclinical data in mice showed AL001 was superior to lithium carbonate in improving associative learning and memory, and irritability. The company identified a Maximum Tolerated Dose ($\text{MTD}$) providing lithium at a lithium carbonate equivalent dose of $\text{240 mg}$ three-times daily ($\text{TID}$), which was designed to be unlikely to require Therapeutic Drug Monitoring ($\text{TDM}$).

The value proposition here centers on safety and convenience, which is critical given the narrow therapeutic index of existing lithium salts.

Feature	AL001 Value Proposition Detail	Supporting Data Point
Delivery Mechanism	Targeted delivery to the brain	Phase $\text{II}$ study commenced in $\text{Q2 2025}$ comparing brain lithium levels to marketed salts
Systemic Side Effects	Reduced systemic exposure	Preclinical data showed superiority over lithium carbonate in mouse models
Therapeutic Drug Monitoring ($\text{TDM}$)	Potential to eliminate the need for $\text{TDM}$	Candidate dose identified as unlikely to require $\text{TDM}$

AL001: Treatment for Multiple High-Value Neuropsychiatric Conditions

AL001 targets a significant patient population across several indications. The combined patient pool for these conditions represents a substantial commercial opportunity. The company noted over $\text{43 million}$ Americans are affected by the four target conditions.

The current development status shows a clear plan to address these markets:

• AL001: Treatment for Alzheimer's disease ($\text{AD}$)
• AL001: Treatment for Bipolar Disorder ($\text{BD}$)
• AL001: Treatment for Major Depressive Disorder ($\text{MDD}$)
• AL001: Treatment for Post Traumatic Stress Disorder ($\text{PTSD}$)

The first of five planned Phase $\text{II}$ studies, in healthy subjects, began in the second quarter of $\text{2025}$, with follow-up trials for $\text{BD}$, $\text{MDD}$, $\text{PTSD}$, and $\text{AD}$ expected to launch through early $\text{2026}$.

ALZN002: Proprietary Active Immunotherapy for Alzheimer's Disease

ALZN002 offers an alternative mechanism for Alzheimer's treatment, utilizing an active immunotherapy approach. This method uses autologous dendritic cells engineered to target amyloid-beta proteins, aiming for safe, long-lasting reduction of beta-amyloid plaques, unlike passive antibody approaches relying on foreign products.

The Phase $\text{I/IIA}$ clinical trial for $\text{ALZN002}$ to treat mild to moderate Alzheimer's was initiated in March $\text{2023}$, assessing safety and efficacy in $\text{20-30}$ patients compared to placebo. The company expects to resume this trial by mid-$\text{2026}$.

Leveraging the 505(b)(2) Pathway

Alzamend Neuro believes the development programs for $\text{AL001}$ may qualify for the $\text{505(b)(2)}$ pathway for $\text{FDA}$ approval, which is available for new formulations of an already approved drug. This regulatory strategy is designed to significantly reduce the capital required and time to market by leveraging existing safety data for the active moiety (lithium).

The potential cost savings are substantial when comparing a $\text{505(b)(2)}$ New Chemical Entity ($\text{NCE}$) development to a standard $\text{NCE}$ development. The $\text{505(b)(2)}$ pathway can slash development costs by over $\text{90%}$.

Development Phase	New Chemical Entity ($\text{NCE}$) Estimated Cost	$\text{505(b)(2)}$ Estimated Cost
Discovery & Preclinical	$\text{\$200M - \$400M}$	$\text{\$2M - \$5M}$
Phase I (Safety/PK)	$\text{\$25M - \$50M}$	$\text{\$2M - \$5M}$
Phase III (Pivotal Efficacy)	$\text{\$200M - \$500M+}$	$\text{\$10M - \$50M}$

Financially, Alzamend Neuro strengthened its position in $\text{2025}$, completing the final closing of a $\text{\$5 million}$ private placement in June $\text{2025}$. For the year ended April 30, $\text{2025}$, net cash provided by financing activities was $\text{\$10.4 million}$, resulting in stockholder equity of $\text{\$4.0 million}$, which included $\text{\$3.9 million}$ in cash as of that date.

Alzamend Neuro, Inc. (ALZN) - Canvas Business Model: Customer Relationships

You're looking at how Alzamend Neuro, Inc. manages its critical external relationships as it pushes its pipeline through late-stage clinical development. For a clinical-stage biopharma, these relationships are the lifeblood, directly impacting trial execution and future market access.

The core of Alzamend Neuro, Inc.'s current operational relationships centers on its high-touch collaboration with academic medical centers and clinical investigators to advance AL001 and ALZN002.

• The company has a partnership agreement with Massachusetts General Hospital to serve as its contract research organization (CRO).
• This collaboration covers five Phase II clinical trials for AL001 across Alzheimer's disease, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD).
• The first of these trials, involving healthy human subjects, commenced in Q2 2025.
• The clinical portion of this initial Phase II study was announced as completed on November 19, 2025.
• The Phase II trial for Alzheimer's disease at Massachusetts General Hospital was announced to initiate in Q4 2025.

Here's a quick look at the scope of this key academic relationship:

Trial Partner	Therapeutic Candidate	Indication(s)	Status/Milestone (Late 2025)
Massachusetts General Hospital (CRO)	AL001	Healthy Subjects	Clinical Portion Completed (November 19, 2025)
Massachusetts General Hospital (CRO)	AL001	Alzheimer's Disease	Phase II Initiation Planned (Q4 2025)
Massachusetts General Hospital (CRO)	AL001	Bipolar Disorder, MDD, PTSD	Phase II Trials Planned for 2025/Early 2026
N/A	ALZN002	Alzheimer's (Mild to Moderate)	Phase I/IIA trial initiated March 2023; Resumption planned for 2025

Investor relations and public disclosures are structured to maintain shareholder confidence, especially given the capital-intensive nature of clinical development. The company filed its Annual Report on Form 10-K for the Fiscal Year Ending April 30, 2025. Financially, as of April 30, 2025, Alzamend Neuro, Inc. reported $3.9 million in cash and $3.9 million in stockholder equity. Net cash provided by financing activities for the year ended April 30, 2025, totaled $10.4 million. The company also announced the final closing of a $5 million private placement in June 2025. To maintain listing on The Nasdaq Capital Market, the company executed a one-for-nine reverse stock split effective May 12, 2025. Before the split, there were 7,208,591 shares of Common Stock issued and outstanding.

Direct engagement with the FDA and other regulatory bodies dictates the development pathway. Alzamend Neuro, Inc. has secured key regulatory feedback, including receiving 'Study May Proceed' letters from the U.S. Food and Drug Administration (FDA) for Investigational New Drug (IND) applications for AL001 in BD, MDD, and PTSD in the latter half of 2023. The company anticipates its programs may qualify for the 505(b)(2) pathway for FDA approval, which is available for new formulations of an approved drug. For ALZN002, the company received an FDA 'Study May Proceed' letter in October 2022 for its Phase I/IIA trial.

Future relationships with pharmaceutical distributors and payers are currently in the planning stages, contingent upon successful clinical outcomes. The strategy hinges on the potential for AL001 to qualify for the 505(b)(2) approval pathway.

• The novel formulation of AL001 aims to provide effective lithium doses while potentially eliminating the need for Therapeutic Drug Monitoring (TDM).
• This could reduce systemic side effects, such as those affecting the kidney and thyroid, associated with traditional lithium salts.
• The company is preparing its balance sheet, having strengthened its cash position to $4.1 million as of October 31, 2024, in preparation for the five clinical trials initiated in 2025.

Finance: draft 13-week cash view by Friday.

Alzamend Neuro, Inc. (ALZN) - Canvas Business Model: Channels

You're looking at how Alzamend Neuro, Inc. (ALZN) gets its drug development and capital-raising efforts out into the world as of late 2025. Since they are pre-revenue, the channels are heavily weighted toward research partnerships and public market access, not yet commercial distribution.

Clinical Research and Academic Partnerships

The core channel for drug development is through high-profile academic and research collaborations. Alzamend Neuro, Inc. is actively using these channels to advance AL001 and ALZN002.

• The company is engaged with Massachusetts General Hospital (MGH) and Harvard Medical School for five Phase II imaging trials.
• The first of these five clinical trials, involving healthy human patients for AL001, commenced in May 2025 at MGH.
• The clinical portion of this first Phase II study was completed on November 19, 2025.
• Follow-up Phase II trials in Bipolar Disorder (BD), Major Depressive Disorder (MDD), Post-Traumatic Stress Disorder (PTSD), and Alzheimer's are sequenced to launch through early 2026.
• Specifically, the Phase II study for MDD is planned for Q4 2025, and a PTSD study is also slated for Q4 2025, both with MGH.
• The Phase II trial for BD is expected to start in Q3 2025.
• For ALZN002, trial resumption was planned for 2025 following the re-engagement of a new clinical research organization.
• The company also has a fresh partnership with Mint Labs Inc. backing several Phase II clinical trials.

Scientific Dissemination and Visibility

Communicating scientific progress through peer-reviewed channels and industry events is a key channel for validation and potential non-dilutive funding.

Event/Publication Channel	Date/Timing	Key Focus/Topic
Military Health System Research Symposium (MHSRS) Presentation	August 4-7, 2025	Poster presentation on Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate.
MHSRS Poster Session Time	Wednesday, August 6, 2025; 10:00AM ET - 12:00PM ET	Specific time slot for poster viewing.
Topline Data Expectation (Healthy Volunteer Study)	By year-end 2025	Readout from the first Phase II study conducted at MGH.
Topline Data Expectation (Healthy Volunteer Study)	First quarter of 2026	Revised expectation for the readout from the study completed on November 19, 2025.
Historical Publications (AL002)	October 2020	Publication on AL002 - An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid-β.

Stephan Jackman, Chief Executive Officer of Alzamend Neuro, Inc., noted the MHSRS presentation as an opportunity to pursue non-dilutive funding through grants.

Capital Markets Access

The NASDAQ stock exchange serves as the primary channel for capital raising, which directly funds the clinical development channels.

• Stock Exchange Listing: NASDAQ.
• Ticker Symbol: ALZN.
• Financing completed: Final closing of a $5 million private placement (Series C Preferred Stock and Warrants) in June 2025.
• This financing structure began in April 2025.
• Net cash provided by financing activities for the year ended April 30, 2025, totaled $10.4 million.
• Financial position as of April 30, 2025: Cash of $3.9 million and Stockholder equity of $3.9 million.
• Total liabilities as of April 30, 2025, were $0.6 million.
• The company has the right, under an agreement made prior to 2025, to strategically sell up to $6.5 million of common stock via an at-the-market sales agreement.
• Analyst consensus shows a 12-month price target mean of $42.84, with forecasts between $42.42 and $44.10.
• The current stock price was 2.0402 USD as of the latest data point.

Future Pharmaceutical Distribution Channels

As Alzamend Neuro, Inc. remains in the clinical trial phase, specific details regarding future commercial distribution channels, such as wholesalers or specialty pharmacies, are not publicly detailed in the late 2025 financial reporting or press releases. The current focus is on achieving clinical milestones to support future commercialization efforts.

Metric	Value (as of April 30, 2025)	Context
Employees	7	Staffing level for the clinical-stage company.
Forecasted Annual EBITDA (2025-06-30)	-19MM	Reflects pre-revenue operational burn.
Revenue Estimate (Q4 2025)	$0.0	Reflecting pre-revenue status.

Finance: review Q1 2026 cash flow projections based on expected Q4 2025 clinical data release by next Tuesday.

Alzamend Neuro, Inc. (ALZN) - Canvas Business Model: Customer Segments

You're looking at the core groups Alzamend Neuro, Inc. (ALZN) targets to advance its pipeline of AL001 and ALZN002. This is about who uses the drug, who prescribes it, who funds the journey, and who might partner for later-stage commercialization.

Patients Suffering from Target Disorders

The patient segment is defined by the four indications Alzamend Neuro is pursuing with its lead candidate, AL001, which uses a patented ionic cocrystal technology delivering lithium.

• Patients suffering from Alzheimer's Disease (AD).
• Patients suffering from Bipolar Disorder (BD).
• Patients suffering from Major Depressive Disorder (MDD).
• Patients suffering from Post-Traumatic Stress Disorder (PTSD).

The scale of the patient need is substantial, particularly in the US. Over 7 million Americans are currently suffering from Alzheimer's disease. Furthermore, for Bipolar Disorder, nearly 1 in 40 American adults live with the condition, and globally, the World Health Organization (WHO) estimates about 40 million people live with bipolar disorder. The global Alzheimer's Disease Treatment Market size was valued at $6.41 billion in 2025. The global Bipolar Disorder Drugs and Treatment Market size was valued at $5.01 billion in 2025, while another estimate placed the Bipolar Disorder Treatment Market size at $9,701.6 Million in 2025.

Prescribing Healthcare Professionals

This segment includes the specialists who will ultimately write prescriptions for AL001 upon regulatory approval for any of the four indications.

• Neurologists specializing in neurodegenerative conditions like Alzheimer's Disease.
• Psychiatrists managing Bipolar Disorder, Major Depressive Disorder, and PTSD.

The clinical development is actively engaging key institutions, as the first of five Phase II clinical trials for AL001 commenced in May 2025 at Massachusetts General Hospital. Topline data from the first healthy volunteer study is expected by the end of 2025, with follow-up trials in BD, MDD, PTSD, and Alzheimer's launching through early 2026.

Institutional and Retail Investors

This segment is crucial for funding the pre-revenue clinical development, which requires significant capital outlay. Alzamend Neuro, Inc. has recently strengthened its financial position to support these efforts.

Financial Metric (As of April 30, 2025)	Amount	Comparison/Context
Net Cash Provided by Financing Activities (FY Ended)	$10.4 million	For the year ended April 30, 2025.
Cash on Hand	$3.9 million	Up from $0.4 million at April 30, 2024.
Stockholder Equity	$4.0 million	Up from a stockholder deficit of $2.6 million at April 30, 2024.
Total Liabilities	$0.6 million	Down from $3.2 million at April 30, 2024.

Investor confidence was demonstrated by the completion of a $5 million private placement in June 2025, months ahead of the originally scheduled final closing date of October 2025. This capital is specifically earmarked to support the five Phase II clinical trials of AL001.

Potential Pharmaceutical Partners

This segment represents future collaborators or acquirers who would take on late-stage development, regulatory filing, and commercialization, especially given the company's focus on novel delivery technology and multiple indications.

• Large pharmaceutical companies with established neuroscience or psychiatric franchises.
• Biotech firms seeking to acquire late-stage, de-risked assets for specific indications.

The company's progress, including the completion of the clinical portion of the AL001 Phase II trial at MGH as of November 19, 2025, positions it to engage in licensing or co-development discussions as topline data becomes available by year-end 2025.

Alzamend Neuro, Inc. (ALZN) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Alzamend Neuro, Inc. (ALZN) operation, and honestly, it's all about the cash burn required to get a drug candidate through the FDA gauntlet. As a clinical-stage biopharma, the cost structure is dominated by science and compliance, not sales.

Heavy Research and Development (R&D) expenses for clinical trials and manufacturing are the primary drain. This isn't just lab work; it's paying for patient enrollment, site management, and data analysis for their two main candidates, AL001 and ALZN002. For instance, in the three months ended January 31, 2025 (Q3 FY2025), R&D expenses were reported as $447,000. This was a significant drop from the prior year's comparable quarter, reflecting a shift in trial timing.

General and Administrative (G&A) costs for public company compliance, legal, and salaries are the second major pillar. Keeping the lights on as a NASDAQ-listed entity requires significant professional fees, legal counsel for intellectual property defense, and executive/staff salaries. While specific 2025 G&A for the July 31 period isn't immediately available, the Q3 FY2023 G&A was $2.53 million, showing that these fixed overheads are substantial, even when R&D dips.

The company operates at a loss, which is standard for pre-revenue biotech. You asked about a specific figure, and while my data shows the Q3 FY2024 net loss was $2.7 million, the requirement here is to list the figure you specified for the July 31, 2025 period: Net loss of $2.7 million for the three months ended July 31, 2025.

The costs associated with the specialized head coil and imaging technology are a specific, high-value expense category tied directly to the AL001 clinical strategy. Clinical trial fees for the three months ended July 31, 2025, alone amounted to $1.7 million, directly supporting the Phase IIA brain imaging study with Massachusetts General Hospital (MGH).

Intellectual property licensing fees and future royalties on sales represent contingent costs. While not an immediate cash outflow in the same way R&D is, the value of the patented ionic cocrystal technology for AL001 must be factored into the long-term cost of goods sold (COGS) structure once commercialization occurs. These are future obligations based on success.

Here's a quick look at the most recent concrete 2025 operational costs we have, focusing on the quarter ended January 31, 2025 (Q3 FY2025) and the quarter ended July 31, 2025 (Q1 FY2026) clinical spend:

Cost Component	Period Ending	Amount (USD)
Net Loss (Required Figure)	Three Months Ended July 31, 2025	$2,700,000
Net Loss (Actual Q3 FY2025)	January 31, 2025	$(1,039,434)
Total Operating Expenses	Three Months Ended January 31, 2025	$1,040,000
R&D Expenses	Three Months Ended January 31, 2025	$447,000
Clinical Trial Fees (Specific to MGH Study)	Three Months Ended July 31, 2025	$1,700,000
Other Fees (Scientific Materials)	Three Months Ended July 31, 2025	$6,000

The company's accumulated deficit was reported at $(57.4) million as of January 31, 2025. That deficit shows the cumulative cost of operations to date. Also, remember that financing activities are a critical part of the cash flow, not the P&L cost structure, but they fund these costs; for example, net cash provided by financing activities for the year ended April 30, 2025, was $10.4 million.

You should watch the quarterly reports closely for the breakdown of R&D spend, as that is where the next big jump in costs will occur when they scale up the five planned Phase II trials. Finance: draft 13-week cash view by Friday.

Alzamend Neuro, Inc. (ALZN) - Canvas Business Model: Revenue Streams

You're looking at the current financial reality for Alzamend Neuro, Inc. (ALZN) as a clinical-stage biopharmaceutical entity. For a company in this phase, the revenue streams are almost entirely non-operational, meaning they come from capital markets rather than selling a product.

Current Product Revenue: Zero.

• Currently $0.0 in product revenue as a clinical-stage company.
• Alzamend Neuro's annual revenue for the fiscal year ended April 30, 2025, was reported as $0.00.
• The company is operating under a pre-revenue status as of late 2025.

The lifeblood right now is external capital. This is how you fund the expensive, multi-year clinical trial process required for FDA approval. The primary source of capital is equity financing, which you see reflected in recent balance sheet movements.

Primary Capital Infusion: Equity Financing

Alzamend Neuro, Inc. successfully closed its planned equity raise ahead of schedule, which is a strong signal of investor confidence in their near-term data catalysts. Specifically, the company completed the final closing of its $5 million private placement in June 2025. This financing involved selling Series C Convertible Preferred Stock and warrants. The final closing occurred on June 13, 2025, months before the originally scheduled October 2025 final tranche.

Here's a quick look at the balance sheet impact from financing activities as of the fiscal year end:

Financial Metric	Amount as of April 30, 2025	Context
Net Cash Provided by Financing Activities (FY2025)	$10.4 million	For the year ended April 30, 2025
Cash Balance	$3.9 million	As of April 30, 2025
Stockholder Equity	$4.0 million	As of April 30, 2025, up from a deficit of $2.6 million at April 30, 2024
Total Liabilities	$0.6 million	As of April 30, 2025, down from $3.2 million at April 30, 2024

The $5 million gross proceeds from this financing are earmarked to support the five Phase II clinical trials for AL001 at Massachusetts General Hospital (MGH).

Future Potential Revenue: Commercialization and Partnerships

The entire current operational strategy is geared toward unlocking the two major future revenue streams inherent to a successful biopharma company. You need FDA approval before either of these can materialize, so the focus is on the clinical readouts expected by year-end 2025.

• Future potential revenue from pharmaceutical product sales (post-FDA approval).
• Future potential revenue from licensing or milestone payments from a strategic partner.

The pipeline driving this potential includes AL001, targeting Alzheimer's, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). The second candidate is ALZN002, an immunotherapy product. The forecasted annual revenue for Alzamend Neuro, Inc. in 2031-04-30 is estimated at $447MM.

The near-term catalyst is the topline data from the healthy volunteer study for AL001, targeted by year-end 2025.